➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Mallinckrodt
Johnson and Johnson
Dow
Medtronic

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 8,821,867

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,821,867
Title:4-1BB binding molecules
Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
Inventor(s): Ahrens; Bianca (Munich, DE), Baxi; Sangita M. (San Diego, CA), Fisher; Timothy Scott (San Diego, CA), Jerome; Richard Michael (East Hampstead, NH), Ladetzki-Baehs; Kathrin (Planegg, DE), Oliphant; Theodore (Galesburg, MI), Sharp; Leslie Lynne (San Diego, CA), Tesar; Michael (Augsberg, DE), Yates; Libbey Anne (Dardenne Prairie, MO), Zulley; Moritz (Munich, DE)
Assignee: Pfizer Inc (New York, NY)
Application Number:13/676,288
Patent Claims:see list of patent claims

Details for Patent 8,821,867

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Pfizer Inc (New York, NY) 2031-09-09 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Pfizer Inc (New York, NY) 2031-09-09 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Pfizer Inc (New York, NY) 2031-09-09 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Pfizer Inc (New York, NY) 2031-09-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKinsey
Express Scripts
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.